Cloud-clone
SKU(재고 관리 코드):LMB243Ra
Magnetic Luminex Assay Kit for Heart-type Fatty Acid Binding Protein (H-FABP) ,etc.
Magnetic Luminex Assay Kit for Heart-type Fatty Acid Binding Protein (H-FABP) ,etc.
Product No.
LMB243Ra
Organism Species
Rattus norvegicus (Rat).
Sample Type
Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
Test Method
Double-antibody Sandwich
Assay Length
3.5h
Detection Range
0.05-50ng/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 0.017 ng/mL.
UOM
1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex
Specificity
This assay has high sensitivity and excellent specificity for detection of Heart-type Fatty Acid Binding Protein (H-FABP) ,etc..
No significant cross-reactivity or interference between Heart-type Fatty Acid Binding Protein (H-FABP) ,etc. and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Heart-type Fatty Acid Binding Protein (H-FABP) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Heart-type Fatty Acid Binding Protein (H-FABP) ,etc. in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 95-105 | 101 |
| EDTA plasma(n=5) | 94-105 | 98 |
| heparin plasma(n=5) | 78-96 | 93 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Heart-type Fatty Acid Binding Protein (H-FABP) ,etc. were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Heart-type Fatty Acid Binding Protein (H-FABP) ,etc. were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Heart-type Fatty Acid Binding Protein (H-FABP) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 93-101% | 87-101% | 82-98% | 90-102% |
| EDTA plasma(n=5) | 99-105% | 83-92% | 92-99% | 98-105% |
| heparin plasma(n=5) | 87-101% | 79-90% | 80-103% | 82-91% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:H-FABP) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
| Magazine | Citations |
| Molecular Medicine Reports | Protective effects of N (2)‑L‑alanyl‑L‑glutamine mediated by the JAK2/STAT3 signaling pathway on myocardial ischemia reperfusion Pubmed:29393473 |
| Oncology Letters | Hydrogen‑rich solution attenuates myocardial injury caused by cardiopulmonary bypass in rats via the Janus‑activated kinase 2/signal transducer and activator of … Pubmed:29928398 |
| FASEB Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure Pubmed: 30230922 |
Share
